PHARMATEK · Gastroentérologie

Calculateur historique du décompte brut des composantes HAPS 2009

Calculer la somme brute de 0 à 3 des composantes sources HAPS 2009 et leur détail de vérification à partir d’un examen initial et d’un ensemble de mesures complets et vérifiés lors d’un premier épisode.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: HAPS 2009 primary-written-method historical abnormal-component arithmetic v1, engine version haps-2009-primary-methods-abnormal-component-count (raw integer 0–3): one examination component when clinician-recorded rebound tenderness is present OR clinician-recorded guarding is present; one hematocrit component when hematocrit is strictly >43.0% for the independently selected original-male threshold category or strictly >39.6% for the independently selected original-female threshold category; and one serum-creatinine component when serum creatinine is >=2.0 mg/dL. Both examination findings must be explicitly present or absent, and the two findings contribute at most one shared component. Hematocrit equality contributes zero; creatinine equality contributes one. The creatinine operator follows the primary written methods, while primary Table 1 instead separates <=2 from >2 mg/dL; that source discrepancy requires clinical signoff. Fixed percent and mg/dL identities only, without conversion or imputation. Output is the three 0/1 components and their raw sum; the original conjunction and any interpretation are excluded.
Population: People for whom acute pancreatitis has already been independently established and applicability of the original 2009 first-attack source context is independently confirmed. The prospective source work used a 394-person single-centre German development cohort and a separate 452-person German multicentre validation cohort. Rebound tenderness and guarding must come from an explicitly completed clinician-performed initial abdominal examination. Hematocrit and serum creatinine must belong to one verified initial hospital measurement set, and the publication's binary hematocrit threshold category must be selected independently rather than inferred by the app. All findings, values, timing, source identities, fixed units, and assay context must be complete and verified.
Limites et exclusions: Use before acute pancreatitis is independently established; a recurrent rather than first independently verified attack; an unverified source-context fit; a later, post-intervention, mixed-time, mismatched, or different-episode examination or measurement set; a missing, unknown, inferred, imputed, default-absent, carried-forward, or nonquantitative source finding or value; or a partial component count. · Patient-reported pain substituted for clinician-recorded rebound tenderness or guarding; one unknown examination finding treated as absent; the original hematocrit threshold category inferred from name, identity, anatomy, laboratory values, or another field; hematocrit entered as a fraction rather than percent points; another hematology value substituted for hematocrit; eGFR, creatinine clearance, urine creatinine, or another renal measure substituted for serum creatinine; converted units; or an unverified measurement identity. · Changing the strict hematocrit boundaries; changing the primary-written-method serum-creatinine >=2.0 mg/dL boundary to the conflicting Table 1 >2 mg/dL row without reviewed versioning; silently resolving that source discrepancy; altering the OR component; or adding an unvalidated graded meaning to totals 1 or 2. · Expansion of the HAPS acronym into a result label, the source conjunction, any positive or negative result, cutoff, threshold interpretation, result group or category, mild or nonsevere label, probability, severity statement, diagnosis, prognosis, reassurance, disposition, admission or discharge decision, ICU decision, imaging, monitoring, management, treatment, or recommendation.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires